Skip to main content
BrainCited

Bacopa monnieri pour Memory Loss

A

Multiple systematic reviews consistently report small-to-moderate improvements in memory recall and processing speed after 8-12 weeks of Bacopa use. A network meta-analysis found high-dose Bacopa (600+ mg/day) significantly improved working and short-term memory.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'ingredient\u003Dbacopa\u002Dmonnieri\u0026condition\u003Dmemory\u002Dloss'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

En conclusion

Multiple systematic reviews consistently report small-to-moderate improvements in memory recall and processing speed after 8-12 weeks of Bacopa use. A network meta-analysis found high-dose Bacopa (600+ mg/day) significantly improved working and short-term memory.

Key Study Findings

Systematic Review
Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer's Treatment: Systematic Review.
Dose: None vs: None Outcome: Cholinesterase inhibition and cognitive improvement Effet: None None

Population: In vivo animal models of AD

Other
Differential Alterations in the Expression of AMPA Receptor and Its Trafficking Proteins in the Hippocampus …
Dose: 200 mg/kg body weight vs: Rotenone-PD mice without BME Outcome: Recognition memory and AMPA receptor expression Effet: None None

Population: Rotenone-induced Parkinson's disease mouse model

Review
Comprehensive Insights into Pathophysiology of Alzheimer's Disease: Herbal Approaches for Mitigating Neurodegeneration.
Dose: None vs: None Outcome: Cognitive decline Effet: None None

Population: Alzheimer's disease patients

Other
Exploring the immunomodulatory potential of Brahmi (Bacopa monnieri) in the treatment of invasive ductal carcinoma.
Dose: Bacopa monnieri (Brahmi) vs: None Outcome: Immunomodulatory effects in breast cancer Effet: None None

Population: Retracted publication - invasive ductal carcinoma

In Vitro
Bacopa monnieri: A promising herbal approach for neurodegenerative disease treatment supported by in silico and …
Dose: Bacopa monnieri phytocompounds vs: Standard AChE inhibitors Outcome: AChE inhibition and neuroprotection Effet: None None

Population: In silico/in vitro NDD study

In Vitro
Bacopa monnieri reduces Tau aggregation and Tau-mediated toxicity in cells.
Dose: None vs: None Outcome: oxidative stress markers Effet: None None

Population: None

Key Statistics

22

Études

1800

Participants

Positive

A

Note

Referenced Papers

International journal of … 2023 13 citations
The Senior care … 2021 2 citations

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Posologies couramment utilisées

general:
300-600 mg/day standardized to 50% bacosides
memorysupport:
300 mg/day for minimum 8-12 weeks

Limite supérieure : Not established; well-tolerated up to 600 mg/day in trials

Posologies étudiées dans la recherche

Posologie Durée Effet N
None -- Positive --
200 mg/kg body weight -- Positive --
None -- Mixed --
Bacopa monnieri (Brahmi) -- Positive --
Bacopa monnieri phytocompounds -- Positive --
None -- Mixed --
None -- Positive --
None 72 weeks Positive --

Moment optimal de prise : With meals; effects require 8-12 weeks of consistent use

Safety & Side Effects

Effets indésirables signalés

  • Gastrointestinal discomfort (nausea, cramping, diarrhea)
  • Dry mouth
  • Fatigue in some individuals
  • Mild sedation at higher doses

Interactions connues

  • Thyroid medications (may increase thyroid hormone levels)
  • Anticholinergic drugs (opposes cholinergic enhancement)
  • Sedative medications (additive CNS depression)
  • Calcium channel blockers (may enhance blood pressure lowering)

Apport maximal tolérable : Not established; well-tolerated up to 600 mg/day in trials

Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.

Frequently Asked Questions

Does Bacopa monnieri help with Memory Loss?
Based on 22 studies with 1,800 participants, there is strong evidence from multiple clinical trials that Bacopa monnieri may support Memory Loss management. Our evidence grade is A (Strong Evidence).
How much Bacopa monnieri should I take for Memory Loss?
Studies have used various dosages. A commonly studied range is 300-600 mg/day standardized to 50% bacosides. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Bacopa monnieri?
Reported side effects may include Gastrointestinal discomfort (nausea, cramping, diarrhea), Dry mouth, Fatigue in some individuals, Mild sedation at higher doses. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Bacopa monnieri and Memory Loss?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 22 peer-reviewed studies with 1,800 total participants. The overall direction of effect is positive.

Related Evidence

Avertissement FDA: Ces déclarations n'ont pas été évaluées par la Food and Drug Administration. Les produits et informations sur ce site ne sont pas destinés à diagnostiquer, traiter, guérir ou prévenir quelque maladie que ce soit. Les notes de preuve présentées sont basées sur notre analyse de la recherche publiée et évaluée par des pairs et ne constituent pas un avis médical. Consultez toujours votre professionnel de santé avant de commencer tout régime de compléments alimentaires.